

Adherium receives \$1.6m Australian R&D Tax Incentive Claim

Melbourne, Australia – 19 January 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a provider of integrated digital health solutions and a world leader in connected respiratory medical devices, has received \$1,627,000 under the Australian R&D Tax Incentive for the financial year ending June 30, 2021 as compared to \$370,000 for the 2020 financial year.

“The work Adherium is completing in Australia plays a significant role in our product strategy, with our next-generation sensors expanding our addressable market from 56% to 80% of the prescription inhaler market for Asthma and COPD,” said Adherium Chief Executive Officer Rick Legleiter. “The increase in the claim year-over-year is reflective of the Company’s serious investment in establishing headquarters in Melbourne and creating jobs by building a research and development team in Australia.”

Adherium designs and manufactures connected respiratory medical devices to improve healthcare outcomes for patients with severe Asthma and COPD. The Company’s products use Bluetooth-enabled sensors to record and provide real-time feedback on inhaled medication adherence and next generation advanced data measurements collected through the Hailie® smart inhaler, creating timely access to data that can help reduce the severity and frequency of respiratory exacerbations and the associated hospital admissions and improve patient management by healthcare providers.

Since 2019, Adherium has been working on sensor and associated firmware and software development in collaboration with Melbourne-based Planet Innovation, an award-winning HealthTech innovation and commercialisation company. Planet Innovation is a Registered Research Provider with Department of Industry, Innovation and Science. The funds received from the claim contribute to completing the research

and development on Adherium's next-generation sensors with advanced data measurements capture.

The R&D Tax Incentive is an Australian Government program developed to assist eligible businesses to access refundable tax offsets for expenditure on eligible research and development activities. This refundable tax offset amounts to 43.5% of the expenditure on eligible research and development activities undertaken during the financial year.

- ENDS -

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution enables access by clinicians, healthcare providers and patients to remotely monitored medication usage, physiological measures, and adherence supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, SDK and API integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries: WE Communications
WE-AUAdherium@we-worldwide.com